XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.4
SEGMENT INFORMATION
 3 Months Ended
Jan. 31, 2023
Segment Reporting [Abstract]  
SEGMENT INFORMATION

11. SEGMENT INFORMATION

 

We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in four reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics and (iv) Other. The following represents selected financial information for our segments for the three months ended January 31, 2023 and 2022 and as of January 31, 2023 and October 31, 2022 (in thousands):

 

   2023   2022 
  

For the Three Months Ended

January 31,

 
   2023   2022 
Net loss:          
CAR-T Therapeutics  $(911)  $(1,611)
Cancer Vaccines   (958)   (1,357)
Anti-Viral Therapeutics   (482)   (904)
Other   (3)   (7)
Total  $(2,354)  $(3,879)
           
Total operating costs and expenses  $2,556   $3,880 
Less non-cash share-based compensation   (1,063)   (2,354)
Operating costs and expenses excluding non-cash share-based compensation  $1,493   $1,526 
Operating costs and expenses excluding non-cash
share based compensation expense:		          
CAR-T Therapeutics  $598   $669 
Cancer Vaccines   588    480 
Anti-Viral Therapeutics   305    372 
Other   2    5 
Total  $1,493   $1,526 

 

           
   January 31,
2023		   October 31,
2022		 
Total assets:          
CAR-T Therapeutics  $11,318   $16,921 
Cancer Vaccines   11,098    9,442 
Anti-Viral Therapeutics   5,750    3,811 
Other   140    238 
Total  $28,306   $30,412 

 

Operating costs and expenses excluding non-cash share-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.